Search

Your search keyword '"Thrombocytopenia -- Care and treatment"' showing total 13 results
Start Over Descriptor "Thrombocytopenia -- Care and treatment" Publisher right vision media
13 results on '"Thrombocytopenia -- Care and treatment"'

1. Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

Subjects
Thrombocytopenia -- Care and treatment, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Gyre Therapeutics announced that China's National Medical Products Administration ('NMPA') has approved Gyre Pharmaceuticals' avatrombopag maleate tablets for the treatment of thrombocytopenia ('TP') associated with chronic liver disease [...]

Published
2024

2. Keymed Biosciences Announced Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM

Subjects
Monoclonal antibodies, Thrombocytopenia -- Care and treatment, Company earnings/profit, General interest, News, opinion and commentary
Abstract

CHENGDU: Keymed Biosciences Inc. (HKEX: 02162) announced that Lei Zhang/Renchi Yang's team from the Institute of Hematology, Chinese Academy of Medical Sciences has recently published a research paper entitled A [...]

Published
2024

5. Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia

Subjects
Viral antibodies, Antibodies, Infants (Newborn) -- Care and treatment, Thrombocytopenia -- Care and treatment, General interest, News, opinion and commentary
Abstract

NEW HAVEN: Rallybio Corporation has issued the following news release: Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients [...]

Published
2023

6. Thrombocytopenia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 27+ Companies Working in the Domain

Subjects
Biotest AG -- Reports, Business -- Research, Thrombocytopenia -- Care and treatment, General interest, News, opinion and commentary
Abstract

New York, USA: DelveInsight Business Research LLP has issued the following news release: Thrombocytopenia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 27+ Companies Working in the Domain The [...]

Published
2023

8. Veralox Therapeutics Announces Favorable Results of Phase 1 Studies of VLX-1005 in Development for Treatment of Heparin-Induced Thrombocytopenia

Subjects
United States. Food and Drug Administration, Heparin -- Product development, Argatroban -- Product development, Thrombocytopenia -- Care and treatment, General interest, News, opinion and commentary
Abstract

FREDERICK: Veralox Therapeutics has issued the following news release: Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat serious immuno-inflammatory diseases with significant unmet medical needs, today [...]

Published
2022

10. HUTCHMED (China) Limited: VOLUNTARY ANNOUNCEMENT HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia (Stock Code: 13)

Subjects
Securities law, Thrombocytopenia -- Care and treatment, General interest, News, opinion and commentary
Abstract

Hong Kong: HUTCHMED (China) Limited has issued the following announcement: HUTCHMED (China) Limited ('HUTCHMED') today announces that the Center for Drug Evaluation of China's National Medical Products Administration ('NMPA') has [...]

Published
2022

11. Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia

Subjects
Kissei Pharmaceutical Company Ltd. -- Product development, Rigel Pharmaceuticals Inc. -- Product development, Biotechnology industry -- Product development, Clinical trials, Thrombocytopenia -- Care and treatment, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

SOUTH SAN FRANCISCO: Rigel Pharmaceuticals, Inc. has issued the following news release: Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that its collaboration partner, Kissei Pharmaceutical Co., Ltd. ('Kissei'), has released [...]

Published
2021

12. CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia

Subjects
United States. Food and Drug Administration, Biological products industry, Drug approval, Thrombocytopenia -- Care and treatment, General interest, News, opinion and commentary
Abstract

SEATTLE: CTI BioPharma Corp. has issued the following news release: CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has completed a rolling New Drug Application ('NDA') submission to the [...]

Published
2021

13. Veralox Therapeutics Announces IND Submission for VLX-1005 to Treat Heparin-Inducted Thrombocytopenia

Subjects
United States. Food and Drug Administration, Anticoagulants (Medicine), Clinical trials, Thrombocytopenia -- Care and treatment, General interest, News, opinion and commentary
Abstract

FREDERICK: Veralox Therapeutics has issued the following news release: Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical [...]

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results